3023592
Last Update Posted: 2017-01-18
Recruiting status is unknown
All Genders accepted | 18 Years-75 Years |
30 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Study of Iguratimod in Sjögren's Syndrome
A single-center, self-control, open-label study of efficacy and safety of Iguratimod in patients with Sjögren's Syndrome
In this study, patients with Sjögren's Syndrome are enrolled and received Iguratimod 25 mg twice a day for 24 weeks. The differences of ESSPRI (EULAR Sjogren's Syndrome Patient Reported Index) score, ESSPRI(EULAR Sjogren's Syndrome Patient Reported Index) score, unstimulated salivary flow rate, Schirmer's test SF-36 score and HAQ score between baseline and week 24 are evaluated to determine the efficacy of Iguratimod in patients with Sjögren's Syndrome.
Eligibility
Relevant conditions:
Sjogren's Syndrome
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Data sourced from ClinicalTrials.gov